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Summary
 
Several inflammatory cytokines, most notably tumor necrosis factor (TNF) and IL-1, induce
anorexia and loss of lean body mass, common manifestations of acute and chronic inflamma-
tory conditions. In C57BL/6 female mice, the administration of TNF, IL-1, and, to a lesser ex-
tent, leukemia inhibitory factor (LIF), produced a prompt and dose-dependent increase in se-
rum leptin levels and leptin mRNA expression in fat. IL-10, IL-4, ciliary neurotrophic factor,
and IL-2, cytokines not known to induce anorexia or decrease food intake, had no effect on
leptin gene expression or serum leptin levels. After administration of 
 
Escherichia coli
 
 lipopolysac-
charide (LPS), leptin gene expression and leptin levels were increased. These findings suggest
that leptin levels may be one mechanism by which anorexia is induced during acute inflamma-
tory conditions.
 
A
 
norexia and loss of lean body mass are hallmark mani-
festations of acute or chronic disease including infec-
tion or cancer. The role of TNF, IL-1, IL-6, and leukemia
inhibitory factor (LIF) as endogenous mediators of the
host response to infection or malignancy has been exten-
sively studied (1–8). Chronic administration of TNF or
LIF to mice (6, 9, 10), or IL-1 to rats (2, 11) results in
significant anorexia and weight loss. Mice engrafted with
Chinese hamster ovary (CHO) cells genetically engineered
to produce TNF, IL-6, or LIF demonstrate profound wasting
comparable to chronic starvation or cancer cachexia (12–14).
Alternatively, anti-TNF antibodies and a receptor antagonist
against IL-1 ameliorate the manifestations of cancer cachexia
in mice (15, 16). Also, cachectic patients with HIV-related
lymphoma treated with anti-IL-6 antibodies demonstrate
weight gain without change in tumor burden (17).
Though evidence has mounted that inflammatory diseases
mediate energy and weight dysregulation through their
associated cytokines, the mechanisms are unknown. Many
recent studies have suggested that the ob gene product,
leptin, may play a central role in energy regulation (18, 19).
This protein is expressed specifically in white adipose tissue
(18), is strongly correlated with total body fat mass (20, 21),
and when given to lean or 
 
ob/ob
 
 mice reduces food intake
and in the 
 
ob/ob
 
 mice increases basal metabolic rate leading
to weight loss (22–24). Therefore, we investigated the
hypothesis that inflammatory cytokines might elevate lep-
tin, a potential explanation for their anorectic effects.
 
Materials and Methods
 
Animals.
 
Female C57BL/6 mice (10–12 wk/18–22 g) were
housed (5/cage) and raised on open formula rat/mouse ration (Zei-
gler, Gardners, PA) and water ad libitum, with a 12 h light–dark cy-
cle beginning at 6:30 a.m. All experiments were conducted in com-
pliance with the Animal Care and Use Committee of the National
Institute of Health. In the diurnal variation experiment animals had
free access to food. In all other experiments, food was withdrawn 2 h
before onset of the dark cycle. In the refeeding experiment only,
food was reintroduced after 7–7.5 h of fasting. Animals were killed
at indicated timepoints for retroperitoneal fat and serum harvest.
 
Reagents.
 
The following cytokines were obtained: mTNF-
 
a
 
(Genentech, South San Francisco, CA), hIL-1
 
b
 
 (Biologic Re-
sponse Modifiers Program [BRMP], Frederick, MD), hIL-2 (Ce-
tus, Chiron Corp., Emeryville, CA), mIL-10 (BRMP, Frederick,
MD), mIL-4 (BRMP, Frederick, MD), mLIF (Genentech, South
San Francisco, CA), mCNTF (R&D Systems, Minneapolis, MN),
and mIL-6 (BRMP, Frederick, MD). 
 
E. coli
 
 lipopolysaccharide (se-
rotype 0127:B8) was purchased from Sigma (St. Louis, MO).
 
Cytokine Response Studies.
 
After a 7-h fast, mice were given an
i.p. injection of 0.2 ml of a control carrier solution of PBS (Bioflu-
ids, Rockville, MD) with 0.5% endotoxin-free fatty acid–poor BSA
(Calbiochem-Novabiochem, La Jolla, CA) or LPS, or one of the
indicated cytokines.
 
Leptin/Serum Levels.
 
Leptin levels were measured by RIA as
described (20, 21) using the procedure as directed by Linco (St.
Charles, MO), except that all reagents were used at one-half rec-
ommended volume.
 
Reverse Transcriptase–PCR.
 
Total RNA was extracted from
frozen fat tissue samples by the guanidinum–thiocyanate/CsCl
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method. An 
 
ob
 
 gene cDNA probe for Northern blotting was
generated as follows. First strand cDNA was synthesized from
3 
 
m
 
g of total RNA derived from an untreated control group, using
Moloney murine leukemia virus reverse transcriptase (GIBCO
BRL, Gaithersburg, MD) and oligo(dT) priming according to the
directions of the manufacturer. The reaction was carried out at
40
 
8
 
C for 1 h in a final volume of 60 
 
m
 
l PCR mix. Amplification
primers were synthesized using the mouse 
 
ob
 
 gene sequence:
sense, 5
 
9
 
-AATGTGCTGCAGACCCCTGTG-3
 
9
 
, and antisense,
5
 
9
 
-CATTCAGGGCTAACATCCAAC-3
 
9
 
. Hot-start PCR was
performed using the protocol for Ampliwax in the following re-
action: 2.5 
 
m
 
l PCR buffer (10
 
3
 
), 10.5 
 
m
 
l sterile water, 5 
 
m
 
l of
each primer (4 
 
m
 
M), 2 
 
m
 
l dNTP mix (10 mM each dNTP) were
mixed in a PCR microfuge tube, followed by a single Ampliwax
PCR Gem, heated to 80
 
8
 
C, and allowed to cool at room temper-
ature. On the solidified wax layer, 7.5 
 
m
 
l PCR buffer (10
 
3
 
), 56.5
 
m
 
l sterile water, 10 
 
m
 
l cDNA template, and 1 
 
m
 
l Taq polymerase
(5 U/
 
m
 
l) were mixed and heated at 95
 
8
 
C for 5 min, followed by
37 cycles using a 1-min denaturation step at 94
 
8
 
C, a 1-min an-
nealing step at 60
 
8
 
C, and a 2-min extension step at 72
 
8
 
C. An ad-
ditional 8-min extension step at 72
 
8
 
C was added after 37 cycles.
PCR reactions were performed in a thermocycler (Perkin-Elmer
Cetus model 480, Norwalk, CT). A single predicted 500-bp PCR
product was obtained as resolved on a 2% agarose gel. The prod-
uct was cloned with the Invitrogen T/A cloning kit (San Diego,
CA), produced in quantity, purified, random prime labeled with
P32, and used as a cDNA probe for our Northern blots. A quan-
tity of the product was subjected to restriction enzyme analysis for
confirmation of specificity.
 
Northern Blot Analysis.
 
Total RNA was extracted from frozen
fat tissue pooled from each experimental group as described above.
Equal amounts of total RNA (25 
 
m
 
g/lane) were subjected to gel
electrophoresis using 1% agarose gels containing 0.6 M formalde-
hyde. RNA was blotted onto Duralon-UV (Strategene, Inc., La
Jolla, CA) nylon membranes and ultraviolet cross-linked. Hybrid-
ization and autoradiography were performed using standard tech-
niques. Equal loading of RNA was confirmed by ethidium bro-
mide staining of the agarose gel or hybridization of nylon
membranes with a chicken 
 
b
 
-actin cDNA probe (Oncor, Gaith-
ersburg, MD). Each lane represents RNA from tissue pooled
from five or six mice. Each experiment was done between three
to six times with consistent results.
 
Statistical Methods.
 
Individual comparisons were evaluated with
Student’s 
 
t
 
 test using the Statview
 
Ô
 
 program.
 
Results
 
We first examined the characteristics of leptin gene ex-
pression and serum levels under simple physiological ma-
nipulations, including circadian variation in freely feeding
mice and the response to acute starvation and refeeding. As
previously demonstrated at the mRNA level (25), leptin
levels under conditions of ad libitum feeding were lowest
in the middle of light cycle and highest in the middle of the
dark cycle (Fig. 1), consistent with the well-established di-
urnal but primarily nocturnal food intake behavior of ro-
dents (26). When animals were fasted beginning 2 h before
the night cycle, the nocturnal rise was abolished. When 7-h
fasted animals were refed, there was an exuberant increase
in leptin gene expression and serum levels higher than freely
fed controls and were manifest as early as 3 h after feeding
(Fig. 1).
After a 7-h evening fast, mice were treated with a single
intraperitoneal injection of LPS, or multiple cytokines at doses
that have an anorectic effect (Ma, G. and H.R. Alexander,
manuscript in preparation). Fig. 2 shows that leptin levels are
significantly increased by LPS, TNF, IL-1, and LIF in a dose-
related manner. LPS and TNF increased leptin levels nearly
five fold to levels greater than that seen in animals acutely
fasted and refed. IL-1 and LIF increased fasting leptin by
approximately twofold, a level similar to that observed in
fed animals. IL-6 had a trend to increase leptin, which did
not reach significance. LPS administration at sublethal (1 and
10 mg/kg) and lethal doses (20 and 30 mg/kg) produced a
Figure 1. Leptin levels in freely feeding mice at intervals throughout a
24-h period and after short-term fasting and refeeding. The initial point
represents midnight, 5.5 h after beginning the dark cycle in the ad libitum
fed diurnal experiment, 7 h after the commencement of the fast in the
fasting and refeeding experiments, and the beginning of refeeding in the
latter experiment. Each point represents the mean 6 SEM of 6–8 individ-
ually measured mice. Northern blot shows ob gene expression in adipose
tissue from freely fed mice (control), decreased expression after a 7- or 12-h
fast (starved), and increased 5 h after refeeding groups of mice starved for 7 h
(refed 5 h).
Figure 2. Leptin levels after i.p. administration of various cytokines and
LPS. Mice were injected with LPS (mg/kg) or recombinant cytokine in
the doses shown (IL-2, IL-1: U/mouse; TNF, IL-6, LIF, CNTF: mg/kg)
or PBS after a 7-h fast and sera and adipose tissue harvested 5 h later. Fur-
ther details are in Materials and Methods. Each bar represents the mean 6
SEM serum leptin level of 6–7 mice. Significance compared with the
PBS-treated animals is indicated as *P ,0.05, **P ,0.01. 
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dose-dependent increase in 
 
ob
 
 gene expression in fasted
mice (Fig. 3). In this model, 20–30 mg/kg of LPS resulted
in a 30–40% lethality by 72 h after adminstration (data not
shown). These effects were specific, because IL-10 and IL-4,
which generally exhibit anti-inflammatory characteristics,
as well as IL-2 and ciliary neurotrophic factor (CNTF), had
no effect on leptin mRNA expression in retroperitoneal fat
(data not shown) or serum leptin levels (see Fig. 2).
We next examined the time course of effects of TNF
and IL-1 on leptin levels (Fig. 4). After a 7-h fast, mice
were injected with 100 
 
m
 
g/kg of TNF, or 1,000 U of IL-1.
Expression of the leptin gene in retroperitoneal fat in-
creased within 2 h after injection and was maximal 6–8 h
after TNF administration (data not shown), while leptin se-
rum levels reached a maximal three-fold elevation by 7 h,
and subsequently returned toward baseline at 18 h. IL-1 in-
duced a slower increase in leptin to a maximal twofold in-
crease by 10 h, which persisted for at least another 8 h.
 
Discussion
 
The time course and dose-dependent effects of the in-
flammatory cytokines TNF and IL-1 on leptin gene ex-
pression suggest that their anorectic effects may be medi-
ated in part by regulation of leptin gene expression. The
finding that IL-6 and LIF are not as potent as TNF or LPS
in inducing leptin levels or gene expression is not surpris-
ing. Although IL-6 and LIF have pleiotropic inflammatory
properties, have been detected in various acute and chronic
diseases (2, 10), and have been shown to induce tissue
wasting in hosts bearing implantable tumors secreting ei-
ther cytokine (13, 14), the evidence that IL-6 or LIF in-
duce anorexia or mediate cachexia in various disease states
is not consistent (27–29). CNTF, IL-2, IL-4 and IL-10, the
latter two being primarily counterinflammatory cytokines,
have not been shown to have anorectic effects in mice (30–
33) and had no effect on leptin levels or gene expression.
The full syndrome of leptin insufficiency is seen in 
 
ob/ob
 
mice that lack functional leptin. These mice have increased
food-seeking behavior, insulin resistance, hypothermia, de-
creased sympathetic drive, elevated corticosterone, and in-
fertility, all of which tend to normalize with exogenous
leptin (21–23, 34, 35). Acute food restriction in mice, asso-
ciated with low leptin levels, is characterized by the same
abnormalities. In an acutely infected mouse, these abnor-
malities (except infertility) might be anticipated to impair
survival in the face of bacterial infection. In particular, lep-
tin support of brown fat, basal metabolism, and prevention
of hypothermia may be important in preserving the adap-
tive febrile response. We conjecture that cytokine stimula-
tion of leptin to levels at or above seen in the fed state may
have developed to prevent the abnormalities of leptin defi-
ciency during infection, regardless of the food intake.
The leptin receptor, closely related to gp-130 (hetero-
dimer of IL-6 and LIF), is a member of the class I cytokine
group (36). Thus, it seems quite likely that the leptin sys-
tem is ancestrally related to the cytokines. In this context, it
is perhaps not surprising that multiple cytokines influence
leptin levels, as we have demonstrated. The possibility of
the reverse, leptin influence on other cytokines, is plausible
based on the wide distribution of some forms of the leptin
receptor (36), including primitive hematopoetic stem cells
and lymphohematopoetic cell lines (37), and deserves in-
vestigation.
In summary, we have demonstrated that multiple cytokines
documented to induce anorexia increase leptin, a protein
demonstrated to produce anorexia and confirm similar
findings with LPS (38). These results strongly advance the
hypothesis that cytokine induction of leptin may play a sig-
nificant role in the anorexia and cachexia of inflammatory
diseases such as infections, collagen vascular disease, and
cancer. If the cytokine–leptin hypothesis is supported by
further studies, it opens a novel approach to combating this
significant comorbidity of many common diseases.
Figure 3. Effect of LPS on ob
gene expression. After a 7-h fast
mice were injected i.p. with LPS
at the doses indicated and adi-
pose tissue harvested 5 h later as
described. ob gene expression is
low in fasted animals treated
with PBS and increased in a
dose-dependent manner after LPS.
Figure 4. Kinetics of leptin in sera from mice injected with 100 mg/kg
of TNF or 1,000 U of IL-1, after a 7-h fast. All animals were food-deprived
during the experimental period. Each point represents mean 6 SEM lep-
tin level of 5–6 mice, except for the 13-h points, which represent 10–14
mice. Compared with fasted controls, significant differences are indicated
as *P ,0.05. 
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